Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

NCT03773133 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped High number of screen failures

Conditions

Small Cell Lung Cancer and Breast Cancer

Interventions

DRUG: Satoreotide tetraxetan
DRUG: Satoreotide trizoxetan

Sponsor

Ipsen